There are currently 17 clinical trials in North Canton, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Neuro-Behavioral Clinical Research, Inc. and Neurobehavioral Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659
Recruiting
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
Gender:
All
Ages:
Between 12 years and 65 years
Trial Updated:
04/12/2024
Locations: Neuro-Behavioral Clinical Research, North Canton, Ohio
Conditions: Sickle Cell Disease
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: Dr. Shishuka Malhotra, North Canton, Ohio
Conditions: Generalized Anxiety Disorder
Register for Updates
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, North Canton, Ohio
Conditions: Alzheimer's Disease
Register for Updates
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criter... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/03/2024
Locations: Neuro-Behavioral Clinical Research ( Site 0016), North Canton, Ohio
Conditions: Alzheimer Disease
Register for Updates
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
NCT05545111
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
09/15/2023
Locations: Neurocrine Clinical Site, North Canton, Ohio
Conditions: Schizophrenia
Register for Updates